Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JK-1201I + TMZ in Newly Diagnosed GBM
NCT06595186Phase 2Recruiting
- Sponsor
- JenKem Technology
- Start
- Oct 2022
- Primary completion
- Aug 2026
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of JK-1201I in glioblastoma (GBM), sponsored by JenKem Technology. Primary endpoint: Incidence and Grade of Participants with Adverse Events or Serious Adverse Events at 12 months. Started Oct 2022; status: recruiting.
02
Drugs
JK-1201I
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06595186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06595186.